Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603057 · ClinicalTrials.gov registry record
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 115
- Enrollment target
NCT00603057: Completed study, sponsored by University of Michigan Rogel Cancer Center.
NCT00603057 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00603057 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue. This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q SPECT), before treatment and then again during treatment to see if it helps predict how well the treatment works for your cancer and how well your lung functions during treatment. A Computerized Tomography (CT) will also be performed along with both of these procedures to help the researchers see clearly where your cancer or your healthy lung is located. The researchers are also doing blood tests in this study to look for markers in your blood and to see if it helps them in determining your risk of developing side effects from radiation to the lungs. The researchers hope that this study will help them in the future to design radiation treatment plans that provide the best treatment for each individual patient.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2007-05 |
| Est. Completion | 2015-03 |
What the finished NCT00603057 record still lists
NCT00603057 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00603057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00603057 about?
NCT00603057 is a clinical study titled "Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer". Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue. This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and V...
What is the current status of trial NCT00603057?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2007-05. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT00603057?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia